Breast Cancer

Two dose-limiting toxicities were observed, and the maximum tolerated dose was not reached in a study evaluating FS-1502 safety, tolerability, and efficacy.

Data also show statistically meaningful improvements in endocrine symptoms and breast cancer–specific quality of life with acupuncture.

The new recommendation update modifies a 2020 ASCO guideline on the selection of optimal adjuvant chemotherapy and targeted therapy for breast cancer.

A ready-to-dilute formula of SH-105 has been approved by the FDA to treat breast and ovarian cancers.

Updated results from the POSITIVE trial found that patients younger than 35 years had a higher likelihood of achieving pregnancy during an endocrine therapy pause for HR-positive breast cancer.

Data from CAPItello-291 support the approval of capivasertib/fulvestrant for ER-positive, HER2-negative breast cancer in the European Union.

Capivasertib's safety profile in the CAPItello-290 trial was comparable with prior reports of the agent in advanced triple-negative breast cancer.

Patients with hormone receptor-positive breast cancer experienced weight loss when given a plant-based diet plus exercise.

Secondary end points such as overall survival also appear to favor T-DXd among this breast cancer population in the phase 3 DESTINY-Breast06 trial.

Data also show a longer median time to deterioration for patients in the inavolisib arm in phase 3 INAVO120 trial.

A trend towards improved progression-free survival was not noted when pembrolizumab plus sacituzumab govitecan was used to treat patients with HR+ breast cancer.

Increased PFS was noted with abemaciclib plus fulvestrant vs fulvestrant alone in hormone receptor–positive, HER2-negative advanced breast cancer after disease progression on a CDK4/6 inhibitor and endocrine therapy.

Relapse-free survival was improved when anthracycline combo was used to treat MammaPrint high-2–risk, BluePrint Luminal B, HR-positive, HER2-negative breast cancer.

Tiffany A. Traina, MD, FASCO, and Sherry Shen, MD, share their personal and professional journeys to becoming breast oncologists at Memorial Sloan Kettering Cancer Center.

The FDA has set a Prescription Drug User Fee Act date of November 27, 2024, for the inavolisib-based combination in this breast cancer population.

Patients with BRCA-mutated breast cancer can safely undergo assisted reproductive techniques, according to an ESMO study.